Mesa Laboratories MLAB Clinical Genomics — Goodwill Foreign Currency Translation Gain Loss
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mesa Laboratories in its filing.
Tagged under the XBRL concept us-gaap:GoodwillForeignCurrencyTranslationGainLoss.
The official record: Mesa Laboratories’s 10-K, filed June 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mesa Laboratories's clinical genomics — goodwill foreign currency translation gain loss.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mesa Laboratories's clinical genomics — goodwill foreign currency translation gain loss?
- Mesa Laboratories (MLAB) reported clinical genomics — goodwill foreign currency translation gain loss of $0 in Q1 2026.
- How has Mesa Laboratories's clinical genomics — goodwill foreign currency translation gain loss changed year-over-year?
- Mesa Laboratories's clinical genomics — goodwill foreign currency translation gain loss increased by 100.0% year-over-year, from -$3K to $0.
- What is the long-term trend for Mesa Laboratories's clinical genomics — goodwill foreign currency translation gain loss?
- Over 2 years (2023 to 2026), Mesa Laboratories's clinical genomics — goodwill foreign currency translation gain loss has grown at a 100.0% compound annual growth rate (CAGR), from $49K to $196K.
- What does clinical genomics — goodwill foreign currency translation gain loss mean?
- This captures the impact of fluctuations in foreign exchange rates on the carrying value of goodwill denominated in non-functional currencies within the Clinical Genomics segment. It is a non-cash adjustment that reflects the volatility of international operations rather than operational performance.